Aktis Oncology, Inc.NASDAQ: AKTS

Akoustis Reports First Quarter FY24 Results

· Issued by Aktis Oncology, Inc.

Key figures

  • Q1 Revenue Up 26% Year-Over-Year, In-Line with Prior Guidance
  • Guiding Revenue Flat in December Quarter , then 18 to 25% Growth with Record Revenue Projected in March Quarter

On 6ix: 6ix.com/news/akoustis-reports-first-quarter-fy24-results-2023-11-13

  • Q1 Revenue Up 26% Year-Over-Year, In-Line with Prior Guidance
  • Guiding Revenue Flat in December Quarter, then 18 to 25% Growth with Record Revenue Projected in March Quarter
  • Growth, Cost Savings Initiatives, Chips ITC Refund Support Operating Cash Flow Breakeven

Aktis Oncology, Inc. on 6ix

Earlier from Aktis Oncology

Later from Aktis Oncology

All Aktis Oncology news releases